Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Theo de Witte

Showing results (141-150 of 151) with videos related to

Pageof 16
Sort By:
Haematologica|May 4, 2019
Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML), CMML variants and pre-CMML conditionsPeter Valent, Attilio Orazi, Michael R Savona, et al.
Annals of Hematology|July 5, 2014
Clinical and biological impact of TET2 mutations and expression in younger adult AML patients treated within the EORTC/GIMEMA AML-12 clinical trialMariam G Aslanyan, Leonie I Kroeze, Saskia M C Langemeijer, et al.
Haematologica|July 7, 2019
Impact of treatment with iron chelation therapy in patients with lower-risk myelodysplastic syndromes participating in the European MDS registryMarlijn Hoeks, Ge Yu, Saskia Langemeijer, et al.
The New England Journal of Medicine|June 24, 2017
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 MutationRichard M Stone, Sumithra J Mandrekar, Ben L Sanford, et al.
Blood Advances|August 26, 2020
Guideline-based indicators for adult patients with myelodysplastic syndromesKristina Stojkov, Tobias Silzle, Georg Stussi, et al.
Leukemia|March 3, 2021
Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trialRichard A Larson, Sumithra J Mandrekar, Lucas J Huebner, et al.
Hemasphere|January 24, 2025
Somatic mutations and DNA methylation identify a subgroup of poor prognosis within lower-risk myelodysplastic syndromesDavid Rombaut, Sarah Sandmann, Tobias Tekath, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 4, 2013
High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trialRoelof Willemze, Stefan Suciu, Giovanna Meloni, et al.
Blood|February 1, 2023
Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromesAmer M Zeidan, Uwe Platzbecker, Jan Philipp Bewersdorf, et al.
Blood|December 12, 2019
Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemiaKonstanze Döhner, Christian Thiede, Nikolaus Jahn, et al.
Pageof 16

Showing results (141-150 of 151) with videos related to

Sort By:
Pageof 16
Haematologica|May 4, 2019
Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML), CMML variants and pre-CMML conditionsPeter Valent, Attilio Orazi, Michael R Savona, et al.
Annals of Hematology|July 5, 2014
Clinical and biological impact of TET2 mutations and expression in younger adult AML patients treated within the EORTC/GIMEMA AML-12 clinical trialMariam G Aslanyan, Leonie I Kroeze, Saskia M C Langemeijer, et al.
Haematologica|July 7, 2019
Impact of treatment with iron chelation therapy in patients with lower-risk myelodysplastic syndromes participating in the European MDS registryMarlijn Hoeks, Ge Yu, Saskia Langemeijer, et al.
The New England Journal of Medicine|June 24, 2017
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 MutationRichard M Stone, Sumithra J Mandrekar, Ben L Sanford, et al.
Blood Advances|August 26, 2020
Guideline-based indicators for adult patients with myelodysplastic syndromesKristina Stojkov, Tobias Silzle, Georg Stussi, et al.
Leukemia|March 3, 2021
Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trialRichard A Larson, Sumithra J Mandrekar, Lucas J Huebner, et al.
Hemasphere|January 24, 2025
Somatic mutations and DNA methylation identify a subgroup of poor prognosis within lower-risk myelodysplastic syndromesDavid Rombaut, Sarah Sandmann, Tobias Tekath, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 4, 2013
High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trialRoelof Willemze, Stefan Suciu, Giovanna Meloni, et al.
Blood|February 1, 2023
Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromesAmer M Zeidan, Uwe Platzbecker, Jan Philipp Bewersdorf, et al.
Blood|December 12, 2019
Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemiaKonstanze Döhner, Christian Thiede, Nikolaus Jahn, et al.
Pageof 16